Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab in CD38+ Hematological Malignancies
NCT01084252Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2010
- Primary completion
- Dec 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 2 trial of isatuximab in multiple myeloma (MM), non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), sponsored by Sanofi. Started May 2010; status: completed.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)non-Hodgkin lymphoma (NHL)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01084252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01084252.